1. Home
  2. FGF vs AKTX Comparison

FGF vs AKTX Comparison

Compare FGF & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGF
  • AKTX
  • Stock Information
  • Founded
  • FGF 2012
  • AKTX N/A
  • Country
  • FGF United States
  • AKTX United States
  • Employees
  • FGF N/A
  • AKTX N/A
  • Industry
  • FGF Property-Casualty Insurers
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGF Finance
  • AKTX Health Care
  • Exchange
  • FGF Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • FGF 28.0M
  • AKTX 29.5M
  • IPO Year
  • FGF N/A
  • AKTX N/A
  • Fundamental
  • Price
  • FGF $31.15
  • AKTX $2.08
  • Analyst Decision
  • FGF
  • AKTX
  • Analyst Count
  • FGF 0
  • AKTX 0
  • Target Price
  • FGF N/A
  • AKTX N/A
  • AVG Volume (30 Days)
  • FGF 40.6K
  • AKTX 15.6K
  • Earning Date
  • FGF 11-14-2024
  • AKTX 11-26-2024
  • Dividend Yield
  • FGF N/A
  • AKTX N/A
  • EPS Growth
  • FGF N/A
  • AKTX N/A
  • EPS
  • FGF N/A
  • AKTX N/A
  • Revenue
  • FGF N/A
  • AKTX N/A
  • Revenue This Year
  • FGF N/A
  • AKTX N/A
  • Revenue Next Year
  • FGF N/A
  • AKTX N/A
  • P/E Ratio
  • FGF N/A
  • AKTX N/A
  • Revenue Growth
  • FGF 52.56
  • AKTX N/A
  • 52 Week Low
  • FGF $14.21
  • AKTX $1.08
  • 52 Week High
  • FGF $44.00
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • FGF 66.31
  • AKTX 34.80
  • Support Level
  • FGF $16.25
  • AKTX $2.21
  • Resistance Level
  • FGF $18.67
  • AKTX $2.40
  • Average True Range (ATR)
  • FGF 3.34
  • AKTX 0.28
  • MACD
  • FGF 1.03
  • AKTX -0.00
  • Stochastic Oscillator
  • FGF 92.62
  • AKTX 20.15

About FGF FG Financial Group Inc. (NV)

Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Share on Social Networks: